The route changes the evidence needed
FDA’s 2021 VitaStik warning letter included a melatonin diffuser among the inhalation products it identified. The agency’s broader consumer warning explains that wellness vaping claims may be unproven and harmful. [1][2]
A familiar ingredient name does not establish the safety of aerosolizing the complete formulation, including other ingredients or impurities. [1][2]
A wellness label is not therapeutic approval
FDA states that no vaping products are approved to prevent or treat health conditions or diseases. It also warns that inhaled products can cause serious airway symptoms. [1][2]
Do not treat a pen as a verified replacement for an oral preparation. A claimed faster delivery route does not supply the missing safety and efficacy evidence. [1][2]
A capsule study cannot validate an aerosol
Imagine a vape advertisement cites an oral melatonin trial. The trial does not test the device, aerosol composition or inhaled exposure.
| Detail | Interpretation |
|---|---|
| Oral preparation | One route of exposure |
| Vape aerosol | Different formulation and route |
| Therapeutic claim | Needs route-specific evidence |
Sources for this article
- FDA takes action to protect consumers from vaping products with unproven health claims | FDA
Source consulted: 2026-09-18. This is a reference resource, not a claim that we conducted the studies or tested a product. - VitaStik, Inc. - 617713 - 12/01/2021 | FDA
Source consulted: 2026-09-18. This is a reference resource, not a claim that we conducted the studies or tested a product.